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Background: Pulmonary arterial hypertension due to congenital heart disease (CHD-PAH) remains a devastating disease which harbours a poor 
prognosis. We sought to determine early markers to predict mortality in this subset of patients.
Methods: We performed a retrospective cohort study on 31 CHD-PAH patients from the Academic Medical Center selected for advanced therapy 
(84% Eisenmenger syndrome). Before initiation of advanced therapy clinical parameters, including six minute walk distance, laboratory and 
echocardiography results, have been obtained from medical records. The prognostic value of all variables was tested with Cox proportional hazards 
regression analysis.
Results: Of all 31 patients (mean age 39 years, 41% male) with CHD-PAH, 10 patients died 41 ± 19 months later and mean 5-year survival was 
70%. New York Heart Association (NYHA) functional class, urea, creatinine, tricuspid annular plane systolic excursion (TAPSE), tissue doppler imaging 
S’ and log NTproBNP have been shown independent predictors for survival, see Table.
Conclusion: Even on advanced therapy, CHD-PAH patients have a high mortality rate. Several routine parameters are found determinants of 
mortality in adults with CHD-PAH. 
Biomarkers Hazard Ratio Confidence Interval p-value
NYHA functional class 7.00 1.94 - 25.21 0.03
Age 1.01 0.96 - 1.07 0.62
Six minute walk distance 0.99 0.99 - 1.00 0.18
Log NTproBNP 1.001 1.00 - 1.01 0.01
Urea 1.23 1.10 - 1.37 < 0.01
Creatinine 1.04 1.01 - 1.06 < 0.01
Hemoglobin 0.99 0.75 - 1.32 0.97
Tissue Dopple Imaging S’ 0.64 0.46 - 0.90 0.01
TAPSE 0.86 0.76 - 0.97 0.01
